Drug intelligence / Profile preview

toripalimab + bevacizumab + irinotecan

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Toripalimab + bevacizumab + irinotecan is a combination therapy regimen being investigated for the treatment of advanced colorectal cancer, specifically in patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR). The regimen consists of toripalimab, a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to restore immune response; bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis; and irinotecan, a cytotoxic chemotherapy agent that inhibits DNA topoisomerase I. This combination is being evaluated by Peking University Cancer Hospital & Institute in both neoadjuvant and adjuvant settings, showing high pathological complete response rates in early clinical trials (NCT04988191).

Other names: toripalimab-Peking University-colorectal cancerToripalimab + Bevacizumab + Chemotherapy

Targets

PDCD1 (Programmed cell death protein 1 receptor)TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on toripalimab + bevacizumab + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on toripalimab + bevacizumab + irinotecan.

Explore the full profile